A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis

BACKGROUND & AIMS: Primary sclerosing cholangitis (PSC) is a rare, cholestatic liver disease with no currently approved therapies. Obeticholic acid (OCA) is a potent farnesoid X receptor (FXR) agonist approved for the treatment of primary biliary cholangitis. We investigated the efficacy and saf...

Descripción completa

Detalles Bibliográficos
Autores principales: Kowdley, Kris V., Vuppalanchi, Raj, Levy, Cynthia, Floreani, Annarosa, Andreone, Pietro, LaRusso, Nicholas F., Shrestha, Roshan, Trotter, James, Goldberg, David, Rushbrook, Simon, Hirschfield, Gideon M., Schiano, Thomas, jin, Yuying, Pencek, Richard, MacConell, Leigh, Shapiro, David, Bowlus, Christopher L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8157171/
https://www.ncbi.nlm.nih.gov/pubmed/32165251
http://dx.doi.org/10.1016/j.jhep.2020.02.033

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8157171/
https://www.ncbi.nlm.nih.gov/pubmed/32165251
http://dx.doi.org/10.1016/j.jhep.2020.02.033

Ejemplares similares